InterSystems, eHealth Technologies align on images, informatics

| | Health Exec | Digital Transformation

InterSystems and eHealth Technologies have partnered to provide access to images such as x-rays, CT scans, MRIs and ultrasounds via InterSystems' HealthShare informatics platform, which is currently used by hospitals, integrated delivery networks and health information exchanges.

Using eHealth Technologies’ eHealth Solutions, images are delivered along with results, allowing providers access to view and collaborate using a diagnostic-quality, web-based application. In addition, the companies said that emergent image delivery will support emergency care providers by providing images prior to report generation.

The digital imaging capability will be available on InterSystems HealthShare in the fall, according to the companies.

 

 

Related Content

2024 in AI weirdness: ‘Insane’ ChatGPT and mutant rat genitals were only the beginning
10 signs AI is ‘eating the world (of venture capital)’
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
ICU diary-keeping: There’s an AI for that
Stanford HAI lookback: Best-read blog posts of 2024

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.